Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zennea Technologies
Vancouver, British Columbia, Canadacreativedestructionlab.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Zennea Technologies has completed a preliminary clinical trial evaluating the safety and tolerability of its ZENS transcutaneous nerve stimulator for primary snorers and mild OSA patients, demonstrating reduction in snoring during active use. The company is preparing for more extensive trials and FDA approval.
- Therapeutic areas
- Pulmonology
- Modalities
- DeviceNon-pharmacological therapyTranscutaneous neurostimulation device
- Industry
- Therapeutic Medical Devices
02
Partnerships
HAX hardware accelerator programCreative Destruction Lab/HATCH startup accelerator at UBC
Beyond the preview
Go deeper on Zennea Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zennea Technologies.